Literature DB >> 31686536

Drug-coated balloons for coronary artery disease: current concepts and controversies.

Dario Buccheri1, Renzo M Lombardo1, Bernardo Cortese2.   

Abstract

Drug-coated balloons (DCBs) are a novel development for percutaneous coronary intervention. The first successful application was in-stent restenosis but in recent years, strong evidence has been released for its use in native small-vessels disease. Additional applications such as acute myocardial infarction, chronic total occlusion and bifurcation lesions are still under investigation. This article reviews the key studies evaluating the role of DCBs in several settings and reports on interesting cases where DCBs showed positive results for high-risk patients with neoplasm, as well as with high bleeding risk, planned surgery or renal injury. We also highlight a new biodegradable therapy for coronary bifurcation treatment, in which a bioresorbable vascular scaffold is implanted in the main branch, completed with a DCB angioplasty in the side branch when a treatment is deemed necessary.

Entities:  

Keywords:  BVS; CAD; DCB; ISR; PCI; bioresorbable vascular scaffold; coronary artery disease; drug-coated balloon; in-stent restenosis; percutaneous coronary intervention

Mesh:

Substances:

Year:  2019        PMID: 31686536     DOI: 10.2217/fca-2019-0009

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  1 in total

1.  Clinical Outcomes of Drug-Coated Balloon Treatment After Successful Revascularization of de novo Chronic Total Occlusions.

Authors:  Eun Jung Jun; Eun-Seok Shin; Eu-Vin Teoh; Youngjune Bhak; Song Lin Yuan; Chong-Mow Chu; Scot Garg; Houng Bang Liew
Journal:  Front Cardiovasc Med       Date:  2022-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.